A natural inhibitor of vascular smooth muscle cell proliferation

Circulation

Volumn 112, Issue 7, 2005, Pages 1030-1039

  Öllinger, Robert ^a,b,d   Bilban, Martin ^a   Erat, Anna ^a   Froio, Alberto ^a   McDaid, James ^a   Tyagi, Shivraj ^a   Csizmadia, Eva ^a   Graça Souza, Aurelio V ^a   Liloia, Angela ^a   Soares, Miguel P ^c   Otterbein, Leo E ^a   Usheva, Anny ^a,d   Yamashita, Kenichiro ^a   Bach, Fritz H ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^d NONE   (United States)

Author keywords

Arteriosclerosis; Bilirubin; Cell cycle; Muscle, smooth; Signal transition

Indexed keywords

BILIRUBIN; BILIVERDIN; HEME; HEME OXYGENASE; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NATURAL PRODUCT; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; BALLOON DILATATION; BLOOD VESSEL INJURY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; HYPERBILIRUBINEMIA; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; CELL DIFFERENTIATION; CYTOLOGY; DRUG EFFECT; GUNN RAT; LEWIS RAT; WISTAR RAT;

ANIMALS; BILIRUBIN; BILIVERDINE; CELL DIFFERENTIATION; MALE; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, GUNN; RATS, INBRED LEW; RATS, WISTAR;

EID: 23844507814     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.528802     Document Type: Article

References (38)

1. World Health Organization. The World Health Report 2003: Shaping the Future. Geneva. Switzerland: World Health Organization; 2003:154-159.
2. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engt J Med. 1994;330:1431-1438.
3. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation. 1998;98:82-89.
4. Sriram V, Patterson C. Cell cycle in vasculoproliferative diseases: potential interventions and routes of delivery. Circulation. 2001;103:2414-2419.
5. Yet SF, Layne MD, Liu X, Chen YH, Ith B, Sibinga NE, Perrella MA. Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling. FASEB J. 2003;17:1759-1761.
6. Durante W. Heme oxygenase-1 in growth control and its clinical application to vascular disease. J Cell Physiol. 2003;195:373-382.
7. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 2001;7:693-698.
8. Liu XM, Chapman GB, Wang H, Durante W. Adenovirus-mediated heme oxygenase-1 gene expression stimulates apoptosis in vascular smooth muscle cells. Circulation. 2002;105:79-84.
9. Barceloux DG. Cobalt. J Toxicol Clin Toxicol. 1999;37:201-206.
10. Pislaru S, Janssens SP, Gersh BJ, Simari RD. Defining gene transfer before expecting gene therapy; putting the horse before the cart. Circulation. 2002;106:631-636.
11. Otterbein LE, Zuckerbraun BS, Haga M, Liu F, Song R, Usheva A, Stachulak C, Bodyak N, Smith RN, Csizmadia E, Tyagi S, Akamatsu Y, Flavell RJ, Billiar TR, Tzeng E, Bach FH, Choi AM, Soares MP. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat Med. 2003;9:183-190.
12. Hansen TW. Bilirubin brain toxicity. J Perinatol. 2001;21(suppl 1):S48-S51; discussion S59-S62.
13. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043-1046.
14. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228:568-571.
15. Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T, Itabe H, Kodama T, Maruyama Y. Bilirubin From heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2005;25:155-160.
16. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1-61.
17. Yamashita K, McDaid J, Ollinger R, Tsui TY, Berberat PO, Usheva A, Csizmadia E, Smith RN, Soares MP, Bach FH. Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts. FASEB J. 2004;18:765-767.
18. Yeary RA, Grothaus RH. The Gunn rat as an animal model in comparative medicine. Lab Anim Sci. 1971;21:362-366.
19. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99:16093-16098.
20. Petkova V, Romanowski MJ, Sulijoadikusumo I, Rohne D, Kang P, Shenk T, Usheva A. Interaction between YY1 and the retinoblastoma protein: regulation of cell cycle progression in differentiated cells. J Biol Chem. 2001;276:7932-7936.
21. Palko L, Bass HW, Beyrouthy MJ, Hurt MM. The Yin Yang-1 (YY1) protein undergoes a DNA-replication-associated switch in localization from the cytoplasm to the nucleus at the onset of S phase. J Cell Sci. 2004;117:465-476.
22. Waskiewicz AJ, Cooper JA. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr Opin Cell Biol. 1995;7:798-805.
23. Zhao M, Liu Y, Bao M, Kato Y, Han J, Eaton JW. Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases. Arch Biochem Biophys. 2002;400:199-207.
24. Kato Y, Shimazu M, Kondo M, Uchida K, Kumamoto Y, Wakabayashi G, Kitajima M, Suematsu M. Bilirubin rinse: a simple protectant against the rat liver graft injury mimicking heme oxygenase-1 preconditioning. Hepatology. 2003;38:364-373.
25. Clark JE, Foresti R, Sarathchandra P, Kaur H, Green CJ, Motterlini R. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. Am J Physiol. 2000;278:H643-H651.
26. Phelan D, Winter GM, Rogers WJ, Lam JC, Denison MS. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch Biochem Biophys. 1998;357:155-163.
27. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, Hankinson O. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 1991;252:954-958.
28. Barnes-Ellerbe S, Knudsen KE, Puga A. TCDD blocks androgen-dependent cell proliferation of LNCaP cells through modulation of RB phosphorylation. Mol Pharmacol. 2004;66:502-511.
29. Beohar N, Flaherty JD, Davidson CJ, Maynard RC, Robbins JD, Shah AP, Choi JW, MacDonald LA, Jorgensen JP, Pinto JV, Chandra S, Klaus HM, Wang NC, Harris KR, Decker R, Bonow RO. Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model. Circulation. 2004;109:108-113.
30. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996;8:805-814.
31. Geraldes P, Sirois MG, Tanguay JF. Specific contribution of estrogen receptors on mitogen-activated protein kinase pathways and vascular cell activation. Circ Res. 2003;93:399-405.
32. Zhan Y, Kim S, Izumi Y, Izumiya Y, Nakao T, Miyazaki H, Iwao H. Role of JNK, p38, and ERK in platelet-derived growth factor-induced vascular proliferation, migration, and gene expression. Arterioscler Thromb Vasc Biol. 2003;23:795-801.
33. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoonhoven R, Brenner DA. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology. 2003;37:824-832.
34. Watson L, Herdegen T, Buschmann T, Denger S, Wende P, Jahn L, Kreuzer J. JNK and c-Jun but not ERK and c-Fos are associated with sustained neointima-formation after balloon injury. Eur J Clin Invest. 2000;30:11-17.
35. Izumi Y, Kim S, Namba M, Yasumoto H, Miyazaki H, Hoshiga M, Kaneda Y, Morishita R, Zhan Y, Iwao H. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ Res. 2001;88:1120-1126.
36. Taille C, Almolki A, Benhamed M, Zedda C, Megret J. Berger P, Leseche G, Fadel E, Yamaguchi T, Marthan R, Aubier M, Boczkowski J. Heme oxygenase inhibits human airway smooth muscle proliferation via a bilirubin-dependent modulation of ERK1/2 phosphorylation. J Biol Chem. 2003;278:27160-27168.
37. Azevedo LC, Pedro MA, Souza LC, de Souza HP, Janiszewski M, da Luz PL, Laurindo FR. Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc Res. 2000;47:436-445.
38. Kyaw M, Yoshizumi M, Tsuchiya K, Kirima K, Suzaki Y, Abe S, Hasegawa T, Tamaki T. Antioxidants inhibit endothelin-1 (1-31)-induced proliferation of vascular smooth muscle cells via the inhibition of mitogen-activated protein (MAP) kinase and activator protein-1 (AP-1). Biochem Pharmacol. 2002;64:1521-1531.